Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Experimental Cell Research|January 21, 2014
Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancerNobuaki Ochi, Nagio Takigawa, Daijiro Harada, et al.
Oncotargets and Therapy|March 16, 2013
Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentationHiromichi Yamane, Nobuaki Ochi, Masayuki Yasugi, et al.
Cancer Science|September 17, 2013
Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer modelHiromi Hayakawa, Eiki Ichihara, Kadoaki Ohashi, et al.
Experimental Cell Research|April 29, 2014
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumorsMasayuki Yasugi, Nagio Takigawa, Nobuaki Ochi, et al.
Japanese Journal of Clinical Oncology|August 30, 2014
A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion geneHideko Isozaki, Masayuki Yasugi, Nagio Takigawa, et al.
International Medical Case Reports Journal|June 12, 2013
Obstructive jaundice at the initial presentation in small-cell lung cancerNobuaki Ochi, Nagio Takigawa, Masayuki Yasugi, et al.
Cancer Science|June 21, 2012
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutationDaijiro Harada, Nagio Takigawa, Nobuaki Ochi, et al.
Cancer Research|January 1, 2016
Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine KinasesHideko Isozaki, Eiki Ichihara, Nagio Takigawa, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2010
Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705Katsuyuki Hotta, Katsuyuki Kiura, Nagio Takigawa, et al.
Cureus|June 25, 2025
Phase II Study of Platinum Re-administration in Non-small Cell Lung Cancer Following Chemoimmunotherapy ResistanceKiichiro Ninomiya, Shinobu Hosokawa, Toshihide Yokoyama, et al.
Pageof 2